Chemoradioimmunotherapy in locally advanced pancreatic and biliary tree adenocarcinoma: A multicenter phase II study

Pancreas

Volumn 38, Issue 6, 2009, Pages

  Recchia, Francesco ^a   Sica, Gigliola ^a   Candeloro, Giampiero ^b   Bisegna, Roberta ^c   Bratta, Massimo ^d   Bonfili, Pierluigi ^d   Necozione, Stefano ^d   Tombolini, Vincenzo ^d   Rea, Silvio ^a  

^a Ospedale Civile di Avezzano   (Italy)

^b Fondazione Carlo Ferri   (Italy)

^c UNIVERSITÀ CATTOLICA DEL SACRO CUORE   (Italy)

^d UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CARBOPLATIN; CISPLATIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; INTERLEUKIN 2; ISOTRETINOIN;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BILE DUCT CARCINOMA; BILIARY TREE ADENOCARCINOMA; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; ERYTHEMA NODOSUM; FEBRILE NEUTROPENIA; FEMALE; FEVER; FOLLOW UP; HUMAN; HUMAN TISSUE; HYPOTHYROIDISM; INFECTION; LEUKOPENIA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PSORIASIS; SIDE EFFECT; THERAPY EFFECT; THROMBOCYTOPENIA; THYROIDITIS; TRIACYLGLYCEROL BLOOD LEVEL;

ADENOCARCINOMA; ADULT; AGED; ALGORITHMS; ANTINEOPLASTIC AGENTS; BILIARY TRACT NEOPLASMS; CISPLATIN; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; ISOTRETINOIN; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS;

EID: 68949085150     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e3181abe222     Document Type: Article

References (34)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics. CA Cancer J Clin. 2005;55:10-30.
2. Evans DB, Abbruzzese JL, Willett CG. Cancer of the pancreas. In: De Vita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 6th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2001:1126-1161.
3. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997:2403-2413.
4. Penz M, Kornek GV, Raderer M, et al. Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. Ann Oncol. 2001;12:183-186.
5. Colucci G, Giuliani F, Gebbia V, et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologico dell'Italia Meridionale. Cancer. 2002;94:902-910.
6. Heinemann V, Quietzsch D, Gieseler F, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol. 2006;24:3946-3952.
7. Reyes-Vidal J, Gallardo J, Yanez E, et al. Gemcitabine and cisplatin in the treatment of patients with unresectable or metastatic gallbladder cancer: Results of the phase II Gocchi study 2000-13. Proc Am Soc Clin Oncol. 2003;22:273, (abstr 1095).
8. Tsai TY, Innitti DA, Safran H. Combined modality therapy for pancreatic cancer. Semin Oncol. 2003;30:71-79.
9. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100:3547-3549.
10. Naumov GN, Bender E, Zurakowski D, et al. A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. J Natl Cancer Inst. 2006;98:316-325.
11. Immervoll H, Hoem D, Sakariassen PØ, et al. Expression of the "stem cell marker" CD133 in pancreas and pancreatic ductal adenocarcinomas. BMC Cancer. 2008;8:48.
12. von Bernstorff W, Voss M, Freichel S, et al. Systemic and local immunosuppression in pancreatic cancer patients. Clin Cancer Res. 2001;7(suppl 3):S925-S932.
13. Finke J, Ferrone S, Frey A, et al. Where have all the T cells gone? Mechanisms of immune evasion by tumors. Immunol Today. 1999;4:158-160.
14. Smith KA. Interleukin-2: inception, impact and implications. Science. 1988;240:1169-1176.
15. Rosenberg SA, Lotze MT, Yang JC, et al. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg. 1989;210:474-484.
16. Recchia F, De Filippis S, Rosselli M, et al. Phase IB study of subcutaneously administered interleukin-2 in combination with 13-cis retinoic acid as maintenance therapy in advanced cancer. Clin Cancer Res. 2001;7:1251-1257.
17. Recchia F, Saggio G, Cesta A, et al. Interleukin-2 and 13-cis retinoic acid as maintenance therapy in advanced ovarian cancer. Int J Oncol. 2005;27:1039-1046.
18. Recchia F, Saggio G, Nuzzo A, et al. Multicenter phase 2 study of interleukin-2 and 13-cis retinoic acid as maintenance therapy in advanced non - small-cell lung cancer. J Immunother. 2006;29:87-94.
19. Recchia F, Saggio G, Amiconi G, et al. Multicenter phase II study of chemo-immunotherapy in the treatment of metastatic renal cell carcinoma. J Immunother. 2007;30:448-454.
20. Recchia F, Saggio G, Cesta A, et al. Phase II study of interleukin-2 and 13-cis-retinoic acid as maintenance therapy in metastatic colorectal cancer. Cancer Immunol Immunoth 2007;56:699-708.
21. Recchia F, Saggio G, Candeloro G, et al. Chemoimmunotherapy in the treatment of metastatic gastric cancer. Anticancer Drugs. 2007;18: 597-604.
22. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
23. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Ass. 1958;53:457-481.
24. Moertl CG, Gunderson LL, Mailliard JA, et al. Early evaluation of combined fluorouracil and leucovorin as a radiation enhancer for locally unresectable, residual, or recurrent gastrointestinal carcinoma. The North Central Cancer Treatment group. J Clin Oncol. 1994;12:21-27.
25. Cunningham D, Chau I, Stoken D, et al. Phase III randomized comparison of gemcitabine (GEM) with gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer. Eur J Cancer. 2005;3(suppl 2):S12.
26. Cascinu S, Berardi R, Labianca R, et al. Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial. Lancet Oncol. 2008;9:7-8.
27. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960-1966.
28. Chauffert B, Mornex F, Bonnetain F, et al. Phase III trial comparing initial chemoradiotherapy (intermittent cisplatin and infusional 5-FU) followed by gemcitabine vs gemcitabine alone in patients with locally advanced non metastatic pancreatic cancer: A FFCD-SFRO study. J Clin Oncol. 2006;24:180s 2006 (abstr 4008).
29. Huguet F, André T, Hammel P, et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol. 2007;25:326-331.
30. Cartwright TH, Cohn H, Varkey JA, et al. Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J Clin Oncol. 2002;20:160-164.
31. Saif MW, Black G, Roy S, et al. Phase II study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: up-regulation of thymidine phosphorylase. Cancer J. 2007; 13:247-256.
32. Sporn MB, Roberts AB. Interaction of retinoids and transforming growth factor-A in regulation of cell differentiation and proliferation. Mol Endocrinol. 1991;5:3-7.
33. Disis ML, Kim Lyerly K. Global role of the immune system in identifying cancer initiation and limiting disease progression. J Clin Oncol. 2005;23:8923-8925.
34. + regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol. 2004;22:531-562.